It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The human microbiome contains genetic information that regulates metabolic processes in response to host health and disease. While acidic vaginal pH is maintained in normal conditions, the pH level increases in infectious vaginitis. We propose that this change in the vaginal environment triggers the biosynthesis of anti-vaginitis metabolites. Gene expression levels of Chryseobacterium gleum, a vaginal symbiotic bacterium, were found to be affected by pH changes. The distinctive difference in the metabolic profiles between two C. gleum cultures incubated under acidic and neutral pH conditions was suggested to be an anti-vaginitis molecule, which was identified as phenylacetic acid (PAA) by spectroscopic data analysis. The antimicrobial activity of PAA was evaluated in vitro, showing greater toxicity toward Gardnerella vaginalis and Candida albicans, two major vaginal pathogens, relative to commensal Lactobacillus spp. The activation of myeloperoxidase, prostaglandin E2, and nuclear factor-κB, and the expression of cyclooxygenase-2 were reduced by an intravaginal administration of PAA in the vaginitis mouse model. In addition, PAA displayed the downregulation of mast cell activation. Therefore, PAA was suggested to be a messenger molecule that mediates interactions between the human microbiome and vaginal health.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Woosuk University, Department of Pharmacy, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)
2 Woosuk University, Department of Korean Pharmacy, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)
3 Daegu Catholic University, Department of Pharmacology, School of Medicine, Daegu, Republic of Korea (GRID:grid.253755.3) (ISNI:0000 0000 9370 7312)
4 Woosuk University, Department of Food and Biotechnology, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)
5 Woosuk University, Department of Pharmaceutical Engineering, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)
6 Jeonbuk National University, Department of Oriental Medicine Resources, Iksan, Republic of Korea (GRID:grid.411545.0) (ISNI:0000 0004 0470 4320)
7 Woosuk University, Department of Pharmacy, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511); Woosuk University, Research Institute of Pharmaceutical Sciences, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)